- Home
- BSBR vs TAK Comparison
BSBR vs TAK Comparison
Compare BSBR & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSBR
- TAK
- Stock Information
- Founded
- BSBR 1985
- TAK 1781
- Country
- BSBR Brazil
- TAK Japan
- Employees
- BSBR N/A
- TAK N/A
- Industry
- BSBR Commercial Banks
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- BSBR Finance
- TAK Health Care
- Exchange
- BSBR Nasdaq
- TAK Nasdaq
- Market Cap
- BSBR 43.3B
- TAK 43.3B
- IPO Year
- BSBR 2009
- TAK N/A
- Fundamental
- Price
- BSBR $6.43
- TAK $14.52
- Analyst Decision
- BSBR Strong Buy
- TAK
- Analyst Count
- BSBR 2
- TAK 0
- Target Price
- BSBR $6.00
- TAK N/A
- AVG Volume (30 Days)
- BSBR 566.9K
- TAK 3.4M
- Earning Date
- BSBR 10-29-2025
- TAK 10-30-2025
- Dividend Yield
- BSBR 3.61%
- TAK 1.90%
- EPS Growth
- BSBR 21.12
- TAK N/A
- EPS
- BSBR 0.38
- TAK 0.14
- Revenue
- BSBR $9,251,919,150.00
- TAK $29,846,840,032.00
- Revenue This Year
- BSBR N/A
- TAK $0.01
- Revenue Next Year
- BSBR N/A
- TAK $0.49
- P/E Ratio
- BSBR $8.52
- TAK $202.70
- Revenue Growth
- BSBR 4.43
- TAK N/A
- 52 Week Low
- BSBR $3.75
- TAK $12.80
- 52 Week High
- BSBR $6.44
- TAK $15.69
- Technical
- Relative Strength Index (RSI)
- BSBR 71.06
- TAK 62.71
- Support Level
- BSBR $6.13
- TAK $14.01
- Resistance Level
- BSBR $6.43
- TAK $14.56
- Average True Range (ATR)
- BSBR 0.11
- TAK 0.17
- MACD
- BSBR -0.01
- TAK 0.08
- Stochastic Oscillator
- BSBR 94.96
- TAK 95.50
About BSBR Banco Santander Brasil SA each representing one unit
Banco Santander (Brasil) SA is part of Santander Group, a Spanish bank. It operates across two segments; the Commercial Banking segment, catering to both individual and corporate client and the Global Wholesale Banking segment, which encompasses Investment Banking and Markets operations, including the Treasury and Equity Business Departments. The bank generates majority of its revenue from the Commercial Banking segment and has operations in Brazil and internationally.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.